On April 10, Warshel Institute for Computational Biology, headed by Nobel laureate in Chemistry in 2013 Arieh Warshel, and Kobilka Institute of Innovative Drug Discovery, headed by Nobel laureate in Chemistry in 2012 Brian K. Kobilka, were established at The Chinese University of Hong Kong, Shenzhen. These are the first batch of Nobel laureate research labs at the University.

Warshel Institute for Computational Biology is intended to become one of the world’s most advanced computational biology centers, conducting research on cutting-edge biotechnologies (structural biology, molecular medicine, multi-scale biomolecule simulations, high-throughput Genome Sequencing analysis and translational research of gene diagnosis technology). Professor Warshel wishes to turn this institute into a platform where top researchers from around the world can collaborate and contribute. Meanwhile, the institute is to serve as a hub to boost significant global cooperative projects and to become a multidisciplinary educational center, nurturing young computational biologists.

Aiming to become a world-class theoretical computational biology center, the Warshel Institute for Computational biology focuses on both basic and practical interdisciplinary research, and  cultivates bioinformatics and systems biology talents with comprehensive training. For basic research, the institute pursues computational structural biology, which covers protein structure prediction, protein engineering and activity improvement, enzyme reaction mechanism, enzyme design, molecular simulations of protein and nucleic acids, computer-aided drug design, algorithm development and software service. For practical research, the institute focuses on high-throughput biology and bioinformatics, which applies high-throughput sequence analysis technology in genomics and precision medicine, covering disease pathogenesis, early diagnosis biomarkers and innovative drug development. The institute will also work closely with ally research platforms, such as the on-campus Shenzhen Research Institute of Big Data, Kobilka Institute of Innovative Drug Discovery, Ciechanover Institute of Precision and Regenerative Medicine and off-campus medical institutions, in shaping tight industry-university cooperations that nurture the development of health food, medical and beauty products, plant medicine, drugs and disease gene testing platform in the Guangdong-Hong Kong-Macao Greater Bay Area.